Biotechnology

GeoVax Labs

GeoVax Labs released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.6203 (forecast USD -0.845)

GeoVax Labs released FY2025 Annual Earnings on April 15 (EST), actual revenue USD 2.489 M (forecast USD 1.747 M), actual EPS USD -22.3954 (forecast USD -24.7625)

GeoVax Labs released FY2025 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.5474 (forecast USD -5.3475)

Roth MKM Analyst Maintains Buy Rating on GeoVax Labs, Price Target at $14.00

GeoVax Labs released FY2025 9 Months Earnings on November 13 After-Market EST, actual revenue USD 2.489 M, actual EPS USD -1.1092

GeoVax Labs released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -7.7868 (forecast USD -6.625)

GeoVax Labs to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast Revenue USD 0, EPS USD -0.265

Aschoff Provides Healthcare Industry Stock Analysis and Recommendations

GeoVax Labs released FY2025 Q2 earnings on July 28 After-Market EST, actual revenue USD 852.28 K (forecast USD 533.33 K), actual EPS USD -8.7403 (forecast USD -9)

GeoVax Labs released FY2025 Semi-Annual earnings on July 28 After-Market EST, actual revenue USD 2.489 M, actual EPS USD -0.7889

GeoVax Labs to Release FY2025 Q2 Earnings on July 28 After-Market EST, Forecast Revenue USD 533.33K, EPS USD -0.36

GeoVax Labs Conducts Public Offering of Approximately 9.2 Million Units

GeoVax Labs Announces Patent for Malaria Vaccine

GeoVax Responds to WHO Declaring Monkeypox a Global Health Emergency

GeoVax to present positive immune data of GEO-CM04S1 in CLL patients at EHA

GeoVax Highlights Broad Cross-Protective Immunity of Its Multi-Antigen COVID-19 Vaccine Candidate

D. Boral Capital Downgrades Geovax Labs' Price Target and Rating

GeoVax Terminates BARDA Contract and Reports Q1 Earnings

GeoVax Labs released FY2025 Q1 earnings on May 1 After-Market EST, actual revenue USD 1.637 M (forecast USD 1.25 M), actual EPS USD -11.2039 (forecast USD -16.4375)

GeoVax Labs to release FY2025 Q1 earnings on May 1 After-Market EST, forecast revenue USD 1.25 M, EPS USD -0.6575

Meiwu Tech

Amesite

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Phoenix Asia

Gen Digital - Rights

GOVX

IBBQ

LABU

SBIO

GeoVax Labs (NASDAQ:GOVX) stock is down 13.57% in premarket trading after an 80% rally, following the announcement of a $3M private placement, raising concerns over shareholder dilution. The offering includes approximately 2.03 million shares and warrants for an additional 4.05 million shares. Despite the drop, the stock remains above its 20-day and 50-day SMAs, but is significantly below its 100-day and 200-day SMAs, indicating a long-term downtrend.

benzinga_article

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

SPDR S&P Biotech

Shutterstock

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

Why Is GeoVax Labs Stock Falling Tuesday?

GeoVax Labs, Inc. emphasizes the critical need for scalable domestic vaccine manufacturing and diversified supply capabilities in light of escalating global infectious disease threats, including the Ebola outbreak and mpox developments. CEO David A. Dodd highlighted the importance of their GEO-MVA vaccine candidate, which is advancing towards a Phase 3 trial. The company aims to enhance biodefense preparedness and has received positive feedback from the European Medicines Agency for its regulatory pathway.

GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats

GOSS

LTRN

In Monday's pre-market session, Sunshine Biopharma surged 635.6% to $2.09, while Geovax Labs rose 169.91% to $3.32. Other gainers included Virax Biolabs (+100.71%), AIM ImmunoTech (+45.73%), and Quantum Cyber (+17.05%). Conversely, WORK Medical Tech fell 25.5%, P3 Health Partners dropped 22.53%, and Artelo Biosciences decreased by 17.4%. Citius Pharmaceuticals, Gossamer Bio, and Lantern Pharma also saw declines following their Q1 earnings reports.

Gossamer Bio

Lantern Pharma

AIM ImmunoTech

P3 Health Partners

Virax Biolabs

Citius Pharma

Artelo Biosciences

Sunshine Biopharma

VG Health

Quantum Cyber NV

Picard Medical

WORK Medical Tech

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

Mainz Biomed NV

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

12 Health Care Stocks Moving In Monday's Pre-Market Session

Earnings Watch

GeoVax Labs | 8-K: FY2026 Q1 Revenue: USD 0

GOVXW

GeoVax reported a Q1 2026 net loss of $5.3 million, with cash reserves of $1.3 million. Revenue from government contracts was $0, down from $1.6 million in Q1 2025 due to a contract termination. The company is advancing its GEO-MVA vaccine program and Gedeptin strategies in immuno-oncology. R&D expenses decreased to $3.9 million, while general and administrative expenses fell to $1.4 million. The company plans to initiate a Phase 3 trial for GEO-MVA and continues to focus on Gedeptin's development.

TradingView

GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 Plans

GeoVax Labs | 8-K: FY2025 Revenue: USD 2.489 M

GeoVax Labs reported $2.489 million in revenue for the year, with a net loss of $(21.465) million, an improvement from the previous year. The operating loss was $(21.639) million, attributed to reduced R&D spending. The company is advancing its GEO-MVA program toward Phase 3 and has multiple Phase 2 trials for GEO-CM04S1. The Gedeptin cancer program has completed Phase 1/2 trials. GeoVax has raised capital through equity tranches to support its initiatives, with a cash runway extending into mid-Q2 2026.

GeoVax Labs 10-K: Revenue $2.489M, Net Loss $(21.465) M

GeoVax Labs | 10-K: FY2025 Revenue: USD 2.489 M

ARKG

In Wednesday's after-market session, Staar Surgical (NASDAQ:STAA) led the gainers with a 19.7% increase to $25.0, followed by Healthcare Triangle (NASDAQ:HCTI) up 15.57% to $2.82. Other gainers included AVITA Medical (NASDAQ:RCEL) +12.19%, Talphera (NASDAQ:TLPH) +8.86%, Geovax Labs (NASDAQ:GOVX) +8.44%, and Modular Medical (NASDAQ:MODD) +7.84%. On the downside, Scienture Holdings (NASDAQ:SCNX) fell 8.2% to $0.32, with Zhengye Biotechnology (NASDAQ:ZYBT) down 8.12%. Other losers included RxSight (NASDAQ:RXST), Profusa (NASDAQ:PFSA), Impact BioMedical (AMEX:IBO), and Axe Compute (NASDAQ:AGPU).

GeoVax Labs(GOVX.US)